ProZinc - Boehringer Ingelheim Vetmedica

ProZinc®
(protamine zinc recombinant human insulin)
Description
PROZINC is a protamine zinc insulin that is FDA approved for use in diabetic cats. PROZINC is
a sterile injectable suspension supplied in 10-mL multidose vials. Each mL of PROZINC contains 40 IU
recombinant human insulin.
Advantages
Features
Benefits
PROZINC is a protamine zinc insulin,
which has a duration of effect in the
cat of 10 — 14 hours1
Contains protamine and zinc
Protamine and zinc serve to release insulin
slowly over each treatment period to help
maintain blood glucose levels throughout
the day
Efficacy and safety studies
demonstrated that PROZINC is
effective in controlling hyperglycemia
as either an initial treatment for
newly diagnosed diabetic cats or as
an alternative treatment for poorly
regulated diabetic cats2
Human recombinant insulin source
FDA approved for cats and backed by the
largest prospective study in diabetic cats3
to date
Proven safe and effective for both newly
diagnosed and poorly regulated diabetic cats
Not subject to sourcing constraints of
older, animal-source insulin products, which
means a more reliable supply of product
Confidence and support from Boehringer
Ingelheim Vetmedica, Inc., a trusted
partner in managing feline diabetes
A versatile solution for a variety of
clinical situations
Indications
PROZINC is indicated for the reduction of
hyperglycemia and hyperglycemia-associated
clinical signs in cats with diabetes mellitus.
Dosage & Administration
PROZINC insulin should be mixed by gently
rolling the vial prior to withdrawing each dose
from the vial. Inject subcutaneously on the
back of the neck or on the side of the cat
using a U-40 syringe. Use of a syringe
other than a U-40 syringe will result in
incorrect dosing.
The initial recommended PROZINC dose is
0.1 – 0.3 IU insulin/pound of body weight
(0.2 – 0.7 IU/kg) every 12 hours. The dose
should be given concurrently with or right after
a meal. The veterinarian should re-evaluate
the cat at appropriate intervals and adjust the
dose based on both clinical signs and glucose
nadirs until adequate glycemic control has
been attained.
Further adjustments in the dosage may
be necessary with changes in the cat’s
diet, body weight, or concomitant
medication, or if the cat develops
concurrent infection, inflammation,
neoplasia, or an additional
endocrine or other medical
disorder. Any adjustments
should be made under
a veterinarian’s
supervision.
Warnings
For use in cats only. Keep out of the reach
of children. Accidental injection may cause
hypoglycemia. In case of accidental injection,
seek medical attention immediately. Exposure
to product may induce a local or systemic
allergic reaction in sensitized individuals.
Owners should be advised to observe for signs
of hypoglycemia. Use of PROZINC insulin,
even at established doses, has been associated
with hypoglycemia. An animal with signs of
hypoglycemia should be treated immediately.
Glucose should be given orally or intravenously
as dictated by clinical signs. Insulin should be
temporarily withheld and, if indicated, the
dosage adjusted.
The safety and effectiveness of PROZINC
insulin in kittens and in breeding, pregnant,
and lactating cats has not been evaluated.
Please refer to package insert for complete
product information.
Storage Information:
Store in an upright position under refrigeration
at 36 – 46º F (2 – 8º C). Do not freeze.
Protect from light.
HIGHLIGHTS
•FDA approved for cats
•Predictable glycemic control; PROZINC
has a duration of action identified by
AAHA as appropriate for the majority of
diabetic cats4
•Feline specific — backed by the largest
prospective study in diabetic cats3
•Human recombinant technology — offers
a reliable supply of product
Product Information
NAME
ProZinc®
(protamine zinc
recombinant
human insulin)
CODE
(449911000)
SIZE
10-mL vial
Boehringer Ingelheim Vetmedica, Inc.
2621 North Belt Highway
St. Joseph, MO 64506-2002
Information 1-866-638-2226
Sales Service 1-800-325-9167
Fax 1-800-318-8366
www.ProZinc.us
www.BI-Vetmedica.com
PRO0211002
Nelson RW. Disorders of the endocrine pancreas. In: Nelson RW, Couto CG, eds. Small Animal Internal Medicine, 4th ed.
St. Louis, MO: Mosby Elsevier; 2009:764-802.
1
Nelson RW, Henley K, Cole C, et al. Field safety and efficacy of protamine zinc recombinant human insulin for the treatment
of diabetes mellitus in cats. J Vet Intern Med. 2009;23:787-793.
FOI for NADA 141-297. (PROZINC)
4
Rucinsky R, Cook A, Haley S, et al. AAHA diabetes management guidelines for dogs and cats. J Am Anim Hosp Assoc.
2010;46:215-22
2
3